Advances in the Radiological Evaluation of and Theranostics for Glioblastoma

Hooper, Grayson W.; Ansari, Shehbaz; Johnson, Jason M.; Ginat, Daniel T.

doi:10.3390/cancers15164162

Cited by 5 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to exhibiting overexpression in prostate cancer, this antigen has also been identified in the highly vascularized endothelium of other tumors, most notably glioblastomas. Recent studies have demonstrated the effectiveness of 68 Ga-PSMA PET imaging of gliomas due to the high tumor-to-brain ratio (TBR) of this radiotracer [24]. One theranostic partner for 68 Ga-PSMA is 177 Lu-PSMA-617, a beta-emitting compound containing lutetium that similarly uses PSMA as its target molecule, delivering radiation to the PSMA-expressing tumor cells [25].…”

Section: Theranostic Use In Gliomasmentioning

confidence: 99%

Clinical Theranostics in Recurrent Gliomas: A Review

Hoggarth,

Muthukumar,

Thomas

et al. 2024

Cancers

View full text Add to dashboard Cite

Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of 12–18 months. While contrast-enhanced MRI serves as the standard diagnostic imaging modality for gliomas, it faces limitations in the evaluation of recurrent gliomas, failing to distinguish between treatment-related changes and tumor progression, and offers no direct therapeutic options. Recent advances in imaging modalities have attempted to address some of these limitations, including positron emission tomography (PET), which has demonstrated success in delineating tumor margins and guiding the treatment of recurrent gliomas. Additionally, with the advent of theranostics in nuclear medicine, PET tracers, when combined with therapeutic agents, have also evolved beyond a purely diagnostic modality, serving both diagnostic and therapeutic roles. This review will discuss the growing involvement of theranostics in diagnosing and treating recurrent gliomas and address the associated impact on quality of life and functional recovery.

show abstract

Section: Theranostic Use In Gliomasmentioning

confidence: 99%

Clinical Theranostics in Recurrent Gliomas: A Review

Hoggarth,

Muthukumar,

Thomas

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Recent studies have also shown increasing interest in some neuroradiological parameters, evaluated both prior and after surgery, that seem to play a predictive role in overall survival (OS) and progression-free survival (PFS) [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma

Aiudi,

Iacoangeli,

Dobran

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Glioblastoma is the most common primary brain neoplasm in adults, with a poor prognosis despite a constant effort to improve patient survival. Some neuroradiological volumetric parameters seem to play a predictive role in overall survival (OS) and progression-free survival (PFS). The aim of this study was to analyze the impact of the volumetric areas of contrast-enhancing tumors and perineoplastic edema on the survival of patients treated for glioblastoma. Methods: A series of 87 patients who underwent surgery was retrospectively analyzed; OS and PFS were considered the end points of the study. For each patient, a multidisciplinary revision was conducted in collaboration with the Neuroradiology and Neuro-Oncology Board. Manual and semiautomatic measurements were adopted to perform the radiological evaluation, and the following quantitative parameters were retrospectively analyzed: contrast enhancement preoperative tumor volume (CE-PTV), contrast enhancement postoperative tumor volume (CE-RTV), edema/infiltration preoperative volume (T2/FLAIR-PV), edema/infiltration postoperative volume (T2/FLAIR-RV), necrosis volume inside the tumor (NV), and total tumor volume including necrosis (TV). Results: The median OS value was 9 months, and the median PFS value was 4 months; the mean values were 12.3 and 6.9 months, respectively. Multivariate analysis showed that the OS-related factors were adjuvant chemoradiotherapy (p < 0.0001), CE-PTV < 15 cm3 (p = 0.03), surgical resection > 95% (p = 0.004), and the presence of a “pseudocapsulated” radiological morphology (p = 0.04). Conclusions: Maximal safe resection is one of the most relevant predictive factors for patient survival. Semiautomatic preoperative MRI evaluation could play a key role in prognostically categorizing these tumors.

show abstract

“…Radiologists strive to identify the predominant component of the lesion to determine prognostic factors and categorize the findings according to the RANO criteria, thus providing the most appropriate treatment for the patient. To overcome the aforementioned limitations in the follow-up, incorporating changes measured by advanced MRI and positron emission tomography (PET) imaging, which may precede anatomical changes in tumor volume, shows promise [ 55 , 56 ]. PET may also help to differentiate actual progression from pseudo progression [ 57 ].…”

Section: Introductionmentioning

confidence: 99%

Glioblastoma Therapy: Past, Present and Future

Obrador,

Moreno-Murciano,

Oriol-Caballo

et al. 2024

IJMS

View full text Add to dashboard Cite

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms involved in GB growth, aggressiveness and recurrence. The discussion on therapeutic strategies first covers the SOC treatment and targeted therapies that have been shown to interfere with different signaling pathways (pRB/CDK4/RB1/P16ink4, TP53/MDM2/P14arf, PI3k/Akt-PTEN, RAS/RAF/MEK, PARP) involved in GB tumorigenesis, pathophysiology, and treatment resistance acquisition. Below, we analyze several immunotherapeutic approaches (i.e., checkpoint inhibitors, vaccines, CAR-modified NK or T cells, oncolytic virotherapy) that have been used in an attempt to enhance the immune response against GB, and thereby avoid recidivism or increase survival of GB patients. Finally, we present treatment attempts made using nanotherapies (nanometric structures having active anti-GB agents such as antibodies, chemotherapeutic/anti-angiogenic drugs or sensitizers, radionuclides, and molecules that target GB cellular receptors or open the blood–brain barrier) and non-ionizing energies (laser interstitial thermal therapy, high/low intensity focused ultrasounds, photodynamic/sonodynamic therapies and electroporation). The aim of this review is to discuss the advances and limitations of the current therapies and to present novel approaches that are under development or following clinical trials.

show abstract

Advances in the Radiological Evaluation of and Theranostics for Glioblastoma

Cited by 5 publications

References 75 publications

Clinical Theranostics in Recurrent Gliomas: A Review

Clinical Theranostics in Recurrent Gliomas: A Review

The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma

Glioblastoma Therapy: Past, Present and Future

Contact Info

Product

Resources

About